StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) stock

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.90−0.00 (-0.32%)

Close on Nov 17, 2026Market cap $6.00MP/E –Yield –

FibroBiologics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

FibroBiologics's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.79M. For fiscal 2025 it was -$16.39M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.39M–
FY2024Dec 31, 2024-$11.90M–
FY2023Dec 31, 2023-$6.40M–
FY2022Dec 31, 2022-$4.07M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.29M–
Q1 FY2026Mar 31, 2026-$4.36M–
Q4 FY2025Dec 31, 2025-$3.16M–
Q3 FY2025Sep 30, 2025-$3.97M–
Q2 FY2025Jun 30, 2025-$3.98M–
Q1 FY2025Mar 31, 2025-$5.28M–
Q4 FY2024Dec 31, 2024-$3.07M–
Q3 FY2024Sep 30, 2024-$2.61M–
Q2 FY2024Jun 30, 2024-$1.95M–
Q1 FY2024Mar 31, 2024-$4.28M–
Q4 FY2023Dec 31, 2023-$1.60M–
Q3 FY2023Sep 30, 2023-$1.14M–
Q2 FY2023Jun 30, 2023-$1.63M–
Q1 FY2023Mar 31, 2023-$2.04M–

More FibroBiologics figures

See a number that looks wrong?